Compare TBPH & GDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | GDRX |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.7M | 919.9M |
| IPO Year | N/A | 2020 |
| Metric | TBPH | GDRX |
|---|---|---|
| Price | $18.67 | $2.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $27.80 | $5.07 |
| AVG Volume (30 Days) | 528.0K | ★ 1.9M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.58 | 0.09 |
| Revenue | $80,327,000.00 | ★ $800,651,000.00 |
| Revenue This Year | $70.78 | $2.30 |
| Revenue Next Year | N/A | $2.91 |
| P/E Ratio | $32.28 | ★ $32.03 |
| Revenue Growth | ★ 27.12 | 1.30 |
| 52 Week Low | $7.90 | $2.61 |
| 52 Week High | $20.33 | $5.81 |
| Indicator | TBPH | GDRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.92 | 43.53 |
| Support Level | $17.25 | $2.69 |
| Resistance Level | $19.13 | $2.83 |
| Average True Range (ATR) | 0.65 | 0.10 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 78.72 | 43.66 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.